DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 14.8% in the afternoon session after the company reported underwhelming earnings. The company's revenue grew over 21% year-on-year to $1.21 ...

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

DexCom Inc. (DXCM) reported its third-quarter earnings for 2025, surpassing analysts’ expectations with an EPS of $0.61 compared to a forecasted $0.57, marking a 7.02% earnings surprise. Revenue also ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

Dexcom, the San Diego-based maker of continuous glucose monitors for diabetes patients and prediabetics, announced Wednesday that it is laying off around 350 workers, or 3% of its global workforce.

This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...